Appendix: Target population data

Appendix: Target population data

MabThera-Rituxan/GA101: Follicular Non-Hodgkin s Lymphoma (NHL) 5000 4500 4000 3500 3000 2500 2000 1500 1000 500 22,800 24,700 Incident cases 39,400 21,400 1800 Drug treated indolent 1st-line 19,700 11,800 5,600 7,900 5,700 Drug treated follicular 1st-line 11,300 Drug treated follicular relapsed Sources: Cancer Incidence in Five Continents, Vol. IX, Curado. M. P et al (2007), IARC Scientific Publications No. 160, Lyon, IARC; World Population Prospects; 2008 revision; medium variant; MabThera patient flow model; & patient case market research Q2 2012 Estimates only; based on Census Bureau, SEER, Mattson Jack TA data, and Q1 2012 Rituxan tracking; GNE Hematology Epi Model 2

MabThera-Rituxan/GA101: Diffuse large B-Cell Non-Hodgkin s Lymphoma (DLBCL) 8000 6000 4000 32,900 40,400 19,500 2000 32,100 10,700 20,900,300 10,400 Incident cases DLBCL 1st-line DLCL relapsed Drug treated Sources: Cancer Incidence in Five Continents, Vol. IX, Curado. M. P et al (2007), IARC Scientific Publications No. 160, Lyon, IARC; World Population Prospects; 2008 revision; medium variant; MabThera patient flow model; & patient case market research Q2 2012 Estimates only; based on Census Bureau, SEER, Mattson Jack TA data, and Q1 2012 Rituxan tracking; GNE Hematology Epi Model 3

MabThera-Rituxan/GA101/GDC-0199: Chronic Lymphocytic Leukemia (CLL) 4000 2000 14,900 18,900 1000 12,400 5,400 14,400 8,900 700 Incident cases CLL 1st-line CLL relapsed Drug treated Sources: Cancer Incidence in Five Continents, Vol. IX, Curado. M. P et al (2007), IARC Scientific Publications No. 160, Lyon, IARC; World Population Prospects; 2008 revision; medium variant; MabThera patient flow model; & patient case market research Q2 2012 Estimates only; based on Census Bureau, SEER, Mattson Jack TA data, and Q1 2012 Rituxan tracking; GNE Hematology Epi Model 4

Avastin: Colorectal Cancer (CRC) The potential target population for Avastin in first-line colorectal cancer is ~11800 drug treated patients (4000 /7800 ); the potential target population in second-line colorectal cancer is ~6700 chemo treated patients (25,500 /41,500 ) 15000 12000 11800 9000 9200 7800 6700 6000 3000 4500 4000 mcrc 1L incidence mcrc 1L drug treated 41,500 25,500 mcrc 2L chemo treated Source: Team analysis and SEER Database 1975-2008. WHO mortality database 2008 http://www.who.int/whosis/whosis/; World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/; internal estimates NB: EU Avastin eligibility, no cut is made for patients who are contraindicated for Avastin all drug treated patients are assumed eligible for Avastin 5

Avastin: Non-Small Cell Lung Cancer (NSCLC) The potential target population for Avastin in first-line non-small cell lung cancer is ~10700 non-squamous drug treated patients (5100 /5600 ) 35000 30000 25000 20000 15000 10000 5000 13700 13400 mnsclc incidence 8200 9300 mnsclc non-squamous 10700 5600 5100 mnsclc 1L non-squamous drug treated Top 5 EU mnsclc is defined as stage IIIB/IV NSCLC Sources: SEER Database: Incidence - SEER 17 Regs Research Data (2000-2008) released April 2011; Table 1. Annual Estimates of the Resident Population by Sex and Five-Year Age Groups for the United States: April 1, 2000 to July 1, 2009 (NC-EST2009-01). U.S. Census Bureau, Population Division. Release Date: June 2010; Table 12. Projections of the Population by Age and Sex for the United States: 2010 to 2050 (NP2008-T12). Population Division, U.S. Census Bureau. Release Date: August 14, 2008; UHC and Medicare Claims; 1965-2005 Center for Health Statistics smoking trends data. WHO mortality database 2008 http://www.who.int/whosis/whosis/. World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/. Roche-Genentech Clinical, Patient Chart Audits; internal estimates 6

Avastin HER2-negative metastatic Breast Cancer (mbc) The potential target population for Avastin in first-line HER2-negative metastatic breast cancer is ~66,400 chemo-treated patients (2900 /37,400 ); in second-line HER2-negative metastatic breast cancer the potential target population is ~45,500 chemo treated patients (2300 /22,500 ) 10000 8000 6000 4000 43,800 66,400 37,400 45,500 22,500 2000 4500 2900 2300 mbc HER2-negative incidence mbc HER2-negative 1L chemo treated mbc HER2-negative 2L chemo treated Sources: SEER Database,1994 2002 (raw incidence by Stage of breast cancer and overall survival rates for metastatic patients), Census. WHO, mortality database 2008 http://www.who.int/whosis/whosis/. World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/. Roche-Genentech Clinical, Patient Chart Audits Note: Includes 1L and 2L patient populations only 7

Avastin: Glioblastoma Multiforme (GBM) The potential target population for Avastin in first-line GBM is ~21,400 Avastin-eligible, drug treated incident patients (9,100 /12300 ). The potential target population for Avastin in relapsed GBM is ~13,200 Avastin-eligible, drug treated incident patients ( 5,500 /7,700 ) 6000 4000 27,400 2000 2200 Total diagnosed incident brain & CNS 13,700 12,300 11,500 9,100 Total diagnosed incident GBM 21,400 Avastin-eligible drug treated incident GBM (1L) 13,200 Source(s): Institut de vielle sanitaire : http://www.invs.sante.fr/surveillance/cancers/default.htm, http://www.invs.sante.fr/applications/cancers/projections2010/donnees_localisation/systeme_nerveux_central.pdf, Assoziatione Italiana Registry Tumori: http://www.registri-tumori.it/cms/, http://info.cancerresearchuk.org/cancerstats/types/pancreas/incidence, Gemeinsames Krebsregister Jahresbericht: http://www.berlin.de/gkr/publikationen/jahresberichte/, SEER Cancer Stat Fact Sheet, Cancer of the Brain and Other Nervous System; Mattson Jack Brain Cancer Epidemiology, December 2007, Mattson Jack Cancer Treatment Architecture, December 2007, Avastin Market Planning primary market research; WHO, mortality database 2008 http://www.who.int/whosis/whosis/; World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/; internal estimates Note: Genentech assumes 75%-80% of incident patients are eligible for drug treatment **Avastin for relapsed GBM is not approved in EU 7,700 5,500 Avastin-eligible drug treated incident GBM (Relapse) 8

Avastin: Ovarian Cancer The potential target population for Avastin in front line ovarian cancer is ~3600 drug treated incident patients (17,700 /18,300 ) The potential target population for Avastin in 2 nd -line platinum sensitive ovarian cancer is ~1700 drug treated incident Avastin naïve patients (700 /1000 ) 6000 4000 2000 2200 3600 18,300 1700 26,500 OC incidence 17,700 Front line chemo treated 1000 700 2nd line chemo treated platinum sensitive ** EU label is FL stage IIIb-IV (GOG-218) labels expected to reflect eligibility of ICON7 and OCEANS in 1L and 2LPS, respectively Sources: SEER Database 1975-2002. Mattson-Jack/DaVinci, Cancer!Mpact, December 2006. Census Update 2008. WHO mortality database 2008 http://www.who.int/whosis/whosis/. World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/. Roche-Genentech Clinical, Patient Chart Audits, ZS Epidemiological model, 2010. 9

Avastin: Renal Cell Carcinoma (RCC) The potential target population for Avastin in first-line metastatic renal cell cancer is ~28,100 drug treated incident patients (15,100 /1300 ) 4000 28,100 2000 17,200 1300 15,400 15,100 Newly diagnosed all RCC Drug treated incident stage IV RCC Sources: SEER Database 1975-2002. Mattson-Jack/DaVinci, Cancer!Mpact, December 2006. Census Update 2008. WHO mortality database 2008 http://www.who.int/whosis/whosis/; World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/; internal estimates; Market Planning Quarterly Tracking Studies 10

Herceptin: HER2+ early Breast Cancer (ebc) The target population for Herceptin in HER2+ early (adjuvant) breast cancer is ~7000 patients (3600 /3400 ) 60000 50000 40000 30000 20000 297,500 238,500 23100 227,500 10000 23100 21800 19800 186,500 Total BC incidence Stage I, II, III Drug treated HER2 tested 7000 3400 3600 HER2+ Source: A Breast Cancer Epi Model; Curado. M. P. et al (2007), Cancer Incidence in Five Continents, Vol. IX; World Population; HER2 Forecast Model. Prospects. The 2008 Revision. United Nations Population Division 2009. http://esa.un.org/unpp/. 11

2012 Estimated Incidence HER2+ metastatic Breast Cancer (mbc) The target and population for 1L HER2+ metastatic breast cancer is ~1800 patients (600 de novo and 1200 adjuvant relapse) The target and population for 2L-4L HER2+ metastatic breast cancer is ~2600 patients (~1400 /~1200 ) 2500 2000 1500 1200 11,500 1L Patients (Top5 EU) 1L Patients () Adjuvant relapse De Novo 6,400 3,300 5,400 2,800 1000 500 1200 11,300 3,300 2,800 Stage IV HER2 Tested 1L HER2+ De Novo HER2+ Rx opportunities 5 EU 2L 6,300 700 3L 4,700 3,200 4L 3,250 1,500 Source: A Breast Cancer Epi Model; WHO mortality database 2008 http://www.who.int/whosis/whosis/; World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/; internal estimates Stage IV=newly diagnosed cases of stage IV BC; HER2 Forecast Model 12

2012/2017 estimates for number of patients Herceptin: HER2+ 1L metastatic Gastric Cancer In 2017, the target population for Herceptin in HER2+ metastatic gastric cancer is approximately 9,300 eligible patients (4,900 /4,400 ) 7000 6000 5000 4000 3000 2000 1000 37,900 38,500 21,400 23,300 27,200 34,700 16,200 17,700 3,500 4,400 4,400 4,900 2012 2017 2012 2017 2012 2017 Incident advanced stage patients HER2 tested 9,300 Herceptin eligible Note: HER2 Testing and eligible assumptions differ between and 5 EU; Source: GC Forecast Model. 13

Xeloda: Metastatic Colorectal Cancer (mcrc) The target population for Xeloda in mcrc is ~22400 eligible drug treated incident patients (8000 /14400 ). Of the drug treated population, the target population in first-line and second-line mcrc is ~4000 and ~2600 patients, respectively. 40000 35000 30000 25000 20000 21900 22400 patients 3 rd line+ 1400 1 st line 4000 2 nd line 2600 15000 10000 5000 15000 Drug treated incident CRC 14400 14400 8000 8000 Drug treated mcrc Xeloda eligible mcrc Drug treated patients=all patients who begin a treatment in a new line of therapy Source: Team Analysis, SEER Database 1975-2006; WHO mortality database 2008 http://www.who.int/whosis/whosis/. World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/. Roche-Genentech Clinical, Patient Chart Audits; internal estimates; Curado. M. P., et al (2007), Cancer Incidence in Five Continents, Vol. IX, IARC Scientific Publications No. 160, Lyon, IARC 14

Xeloda: Metastatic Breast Cancer (mbc) The target population for Xeloda in metastatic breast cancer in 2012 is ~19300 eligible drug treated incident patients (10000 /9300 ) 60000 50000 40000 21500 patients 3 rd line+ 1 st line 3100 3800 30000 20000 10000 19300 31600 9300 10000 9300 10000 Drug treated BC Drug treated mbc Xeloda eligible mbc 2 nd line 3100 *Drug treated patients=all patients who begin a treatment in a new line of therapy Adjuvant HER2- patients are drug treated while metastatic HER2- patients are chemo treated. Source: Team Analysis, SEER Database 1975-2006. WHO mortality database 2008 http://www.who.int/whosis/whosis/. World Population Prospects, the 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/; Internal estimates; Curado. M. P., et al (2007), Cancer Incidence in Five Continents, Vol. IX, IARC Scientific Publications No. 160, Lyon, IARC 15

22012 estimates for number of patients Tarceva: Non-Small Cell Lung Cancer (mnsclc) 30000 EGFR mutation positive ~ 11% 5 EU 25000 20000 13700 16500 EGFR mutation negative ~ 89% 15000 10000 9300 9400 5000 13400 Incidence mnsclc* 7200 mnsclc 1st line drugtreated 5100 2100 4300 2800 mnsclc 2nd line drugtreated mnsclc 3rd line +drugtreated EGFR mutation positive ~ 23% EGFR mutation negative ~ 77% *Total metastatic NSCLC newly diagnosed or newly progressed drug treated patients Sources: information, SEER Annual Cancer Review 1975-2006; Census; Mattson Jack; UHC and Medicare Claims; IntrinsiQ; Synovate Tandem. WHO mortality database 2008 http://www.who.int/whosis/whosis/. World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/. Roche-Genentech Clinical, Patient Chart Audits; internal estimates 16

2012 estimates for number of treated newly diagnosed or progressed pancreatic cancer patients Tarceva: Metastatic Pancreatic Cancer The potential target population for Tarceva in first-line metastatic pancreatic cancer is ~6000 newly diagnosed and drug treated patients (2700 /2900 ) 70'000 60'000 5600 50'000 40'000 30'000 35'000 29'000 20'000 10'000 30'000 27'000 9'000 15'000 '0 Total advanced pancreatic patients Advanced pancreatic 1st line Advanced pancreatic 2nd line Advanced =Stage IIIB/IV in and Stage IV in EU Sources: information, SEER Annual Cancer Review 1975-2006; Census; Mattson Jack; UHC and Medicare Claims; IntrinsiQ; Synovate Tandem. WHO mortality database 2008 http://www.who.int/whosis/whosis/. World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/.; internal estimates 17

Zelboraf: 1st line metastatic Melanoma Cancer The target population for Zelboraf in 1L BRAF mutation positive metastatic melanoma is ~9,100 drug treated patients (4,500 /4,600 ) 2000 1800 1600 1400 1200 1000 9,200 9,100 800 600 400 200 8,900 4,600 4,450 mm 1st line drug treated incidence BRAF mutation positive Sources: information from SEER Annual Cancer Review 1975-2008; Census; WHO mortality database 2008 http://www.who.int/whosis/whosis/. World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/. Roche-Genentech Clinical, Patient Chart Audits; internal estimates 18

Zelboraf: Adjuvant Melanoma Cancer The target population for Zelboraf in BRAF mutation positive stage IIc and III melanoma is ~7,100 drug treated patients (2,100 /500 ) 2000 1800 1600 1400 1200 1000 800 600 400 200 11,700 6,600 Incidence (stage IIc and III) 1000 4,100 Drug treated incidence 7,100 500 2,100 BRAF mutation positive Sources: information from SEER Annual Cancer Review 1975-2008; Census; WHO mortality database 2008 http://www.who.int/whosis/whosis/. World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/. Roche-Genentech Clinical, Patient Chart Audits; internal estimates 19

(000) Erivedge (vismodegib): Advanced Basal Cell Carcinoma The target population for Erivedge in metastatic and locally advanced basal cell carcinoma is ~4000 patients (2800 / 1200 ) 2,400 200 1,600 1,200 800 K 1'500 K 40 0 BCC incidence 40 K 12 K 28 K 28K Advanced BCC incidence *Basal cell carcinoma is not tracked in most cancer registries, including SEER. Prevalence is estimated from incidence rates reported in literature and primary market research. Source: BCC Market Sizing Study, W4 2012 & EU5 Market Sizing Study, 2011. Lucas RM et al: Global burden of disease from solar ultraviolet radiation. In: Prüss-Üstün et al (eds.) Environmental Burden of Disease Series No 13. Geneva: WHO 2006; WHO mortality database 2008 http://www.who.int/whosis/whosis/. World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/. Roche-Genentech Clinical, Patient Chart Audits; internal estimates 20

2012 estimates for number of treated newly diagnosed or progressed NSCLC patients MetMAb: Non-Small Cell Lung Cancer (mnsclc) 350'000 300'000 250'000 200'000 137'000 150'000 100'000 93'000 47,500 24,500 50'000 '0 134'000 Incidence mnsclc* 72'000 mnsclc 1st line drug treated 51'000 43'100 mnsclc 2nd line drug treated 25'500 21'000 10'500 22'000 28'300 14'150 mnsclc 2nd line Met Dx+ mnsclc 3rd line+ drug treated mnsclc 3rd line Met Dx+ *Total metastatic NSCLC newly diagnosed or newly progressed patients Sources: information, SEER Annual Cancer Review 1975-2009; Census; Mattson Jack; UHC and Medicare Claims; IntrinsiQ; Synovate Tandem. WHO mortality database 2008 http://www.who.int/whosis/whosis/. World Population Prospects. The 2008 Revision. UN Population Division 2009. http://esa.un.org/unpp/. Roche-Genentech Clinical, Patient Chart Audits; internal estimates 21

Lucentis: Age-related Macular Degeneration (AMD) Of the ~560k patients with wet AMD (wamd), our potential U.S. target patient population is ~280k patients in 2012 60000 50000 56200 17400 New patients Existing patients 40000 30000 20000 38800 33300 10900 27900 8600 10000 22400 19300 wamd population Presenting/ diagnosed population Treated population Source: Klein R et al. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007 Feb;114(2):253-262; Klein R et al. Prevalence of age-related macular degeneration in the population. Arch Ophthalmol 2011 Jan;129(1):75-80; Census; Roche-Genentech Clinical, Patient Chart Audits, 2007 wamd Buying Process; internal estimates 22

Lucentis: Diabetic Macular Edema (DME) Of the ~700k patients with DME, we believe our Lucentis U.S. target population is ~170k patients in 2012 70000 70000 60000 50000 40000 23400 40800 New patients Existing patients 30000 20000 10000 46600 DME population 16300 24500 Vision loss 24100 9600 14500 Presenting/ diagnosed 17000 6800 10200 Treated population Sources: Bressler NM, Varma R, Doan Q, et al. Prevalence of Visual Impairment from Diabetic Macular Edema and Relationship to Eye Care from the 2005-2008 National Health and Nutrition Examination Survey (NHANES) extrapolated to 2012; The Retina Society 45th Annual Scientific Meetings, Washington, DC; October 4 7, 2012 (accepted for presentation); Eye Diseases Prevalence Research Group (EDPRG) paper April 2004; 2008 DME Buying Process; Roche-Genentech Clinical, Patient Chart Audits; internal estimates 23

Lucentis: Retinal Vein Occlusion (RVO) Of the ~290k patients with CRVO, our potential U.S. target patient population is 40k patients in 2012 30000 20000 2012 estimates for CRVO target population 28800 42,400 Of the ~870k patients with BRVO, we believe our potential U.S. target patient population is 50k patients in 2012 100000 80000 60000 2012 estimates for BRVO target population 87100 151,200 10000 24600 CRVO population 6600 5400 4000 3600 29,200 21,500 3000 24,300 18,100 Rate of vision loss Presentation/ Treatment rate Diagnosis rate 40000 20000 719,600 BRVO population 13500 7200 5300 83,200 44,200 52,200 32,700 27,800 20,600 Rate of Presentation/ Treatment rate vision loss Diagnosis rate Existing patients New patients BRVO=Branch Retinal Vein Occlusion; CRVO=Central Retinal Vein Occlusion. Source: Klein R et al. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008 Apr;126(4):513-518; Klein R et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133-141; discussion 141-143; The Branch Vein Occlusion Study Group. (1984). Am J Ophthalmol, 98(3), 271-82; 2008 RVO Buying Process Research; Roche-Genentech Clinical, Patient Chart Audits; internal estimates 24

Rituxan and Actemra: TNF-IR Rheumatoid Arthritis Our global target population for MabThera/Rituxan and Actemra in rheumatoid arthritis is ~900k bio eligible patients. : Target population for MabThera is Bio-IR (2L+: 85k), for ACTEMRA it is all biologics (~190k) : Target Population for Rituxan and Actemra* is BIO IR (2L+: ~330k) (in millions) 2012 estimates for target population 4 3 2.0 90000 60000 BIO-IR (2L+) DMARD-IR (1L) 2 1.3 1.1 37100 1 0 1.9 Diagnosed RA patients 1.5 1.3 Mod-to-Sev RA patients Mod-to-Sev treated RA patients 0.19 0.70 Biologic treated 30000 32700 103,400 8500 *1 st line indication pending FDA approval in October 2012 Sources: 2011 Equinox EPI Research and Modeling, 2011 survey of published RA epidemiology literature including 2010 based study, 2011 literature review of most recent sources (2008-2010), primary market research 2010-2011 (Rheum ATU, GfK rheum report, Synovate Chart Audit, Adelphi, Decision Resources, etc.), Claims data analysis (2011); Updated for BP2012 5EU Sources: RA Bio-Population alignment (based on BlackSwan assessment); RA Tracker Adelphi & Genactis 2011 and 2012 25

Actemra: Systemic Juvenile Idiopathic Arthritis (sjia) : The target sjia patient population is estimated to be ~5,700 who are eligible for treatment with Actemra the first and only FDA approved therapy EU5: The bio eligible sjia sjia target population is estimated to be ~1,500 patients 1200 1000 800 600 2012 potential target population 5,950 EU5 ~7,200 1,480 patients per line 1L ~2.6K 2L ~2.1K 3L ~1.1K 400 200 600 5,700 Prevalent population Diagnosed and treated Sources: : Q4 2011sJIA Market Research, 2010 sjia ad-board, CDC NHANES, Global Epi Group, EU5: GHEP Epidemiology 26

Rituxan: ANCA-Associated Vasculitis 2012 potential target population Label from FDA indicated for GPA and MPA only Actively treated patients may enter remission Patients in remission may re-enter actively treated upon disease flare-up 41K Diagnosed Diagnosed AAV patients in 2012 Eligible for Rituxan 19K WG 15K MPA 7K CS Patients by disease type 18K Active Tx WG/MPA 3K Active Tx CS 20K In remission Actively treated vs. In remission at any given time GPA=Granulomatosis with polyangiitis, MPA=Microscopic polyangiitis, CS=Churg-Strauss syndrome, ANCA=antineutrophil cytoplasmic antibodies Source: Triangulation and analysis using multiple published studies and primary market research, including: Watts, et al. Epidemiology of ANCA-associated Vasculitis. Rheumatic Disease Clinics of North America. 2010, August; 36 (3): 447-461; Koldingsnes, et al. Epidemiology of ANCA associated vasculitis. Norsk Epidemiologi 2008; 18 (1): 37-48; Rituxan AAV Forecast Research, January 2011; Rituxan GPA/MPA Opportunity Assessment, February 2012 27

2014 estimates for number of patients Xolair: Chronic Idiopathic Urticaria (CIU) potential target population 2014 U.S. Xolair eligible patients seen by Target MDs = ~78,500 patients 100000 96120 80000 60000 672,714 605,443 40000 441,973 20000 12578 Diagnosed CU Idiopathic Age 12+ RX treated Non-responsive to RX therapy 78,549 Seen by biologic prescriber Sources include: CIU Market Research with physicians (Q2 2012), Genentech Burden of Illness Report (2010), Greaves (2007), Tong (1997), Kaplan (2002), Najib (2009), Xolair team input 28

Xolair: Allergic asthma 2012 U.S. Xolair eligible patients seen by Target MDs = ~38200 patients 2012 potential target population 2000 18,552 1500 Treated 54% 1000 1078 Moderate/Severe 40% 500 431 Uncontrolled 55% IgE Mediated 2,217 60% 67% 43% 1,330,891,382 Diagnosed Asthmatics (12+) Treated Asthmatics Moderate and Severe Uncontrolled Allergic Within dosing table Seen by ALs, PUDs, and select PCPs Sources include: Department of Health & Human Services, Vital & Health Statistics, Dec 2006, Trends in Asthma Morbidity & Mortality, August 2007, REACT, AAAAI, TENOR, IMS Dx. Updated prevalence based on CDC Data Jan 2011 29

Lebrikizumab: Severe uncontrolled adult asthma 2500 Forecasted estimates for target population 2000 1500 1000 1323 500 10,152 Treated asthmatics 4,428 ~200* 1,204 1,442,793 Treated w high dose ICS Uncontrolled * Lebrikizumab eligible patients (periostin high) are a subset of this population Sources: Department of Health & Human Services, Vital & Health Statistics, Dec 2006, Trends in Asthma Morbidity & Mortality, August 2007, REACT, AAAAI, TENOR, IMS Dx. Updated prevalence based on CDC Data Jan 2011, Phase II MLLY trial, January 2011 Market Research 30

Patients (000s) Schizophrenia The target population of diagnosed Schizophrenic patients with residual symptoms is ~2.4M patients (1,323M /180M EU) 500 2012 potential target population 400 Target patient population 300 1,986 1,847 1,588 ~2.4m 200 180 100 2,375 2,197 1,889 1,323 Schizophrenic prevalence Schizophrenics diagnosed Treated schizophrenics Schizophrenics with Neg and/or Pos symptoms Sources: Decision Resources, Data Monitor, Roche Epidemiology Group Sources: McGrath et. al., 2008 (Prevalence); Adelphi time to mortality data (Diagnosed); WK PLD Analysis 2010, Adelphi Database 2010, Weiden & Olfson et al., 1990, ECA, 1991, Internal Patient Flow Model (Treatment Rate); Internal Schizophrenia Chart Audit (residual symptoms) 31

2nd generation anti-cd20: Relapsing Multiple Sclerosis (RMS) Potential target population for 2nd generation anti-cd20 for Relapsing Multiple Sclerosis (RMS) is ~47500 patients (250,300 /22300 EU) 70000 60000 50000 40000 30000 20000 10000 29400 30600 ~47500 22300 250,300 Diagnosed prevalence Treated population Source: Genentech/Roche internal assumptions 32

2nd generation anti-cd20: Primary Progressive Multiple Sclerosis (PPMS) Potential target population for 2nd generation anti-cd20 for Primary Progressive Multiple Sclerosis (PPMS) is ~ 38,400 patients (18,400 /2000 EU5) 12000 10000 8000 6000 6500 4000 2000 38,200 Prevalence ~38,400 2000 18,400 Treated population Source: Genentech/Roche internal assumptions 33

No. of Patients in 2012 (000s) Alzheimer s Disease target population The target population of diagnosed, treated Mild, Moderate and Severe Alzheimer s patients is ~1,20000 2012 potential target population 300 2,500,352 Alzheimer's Severe 200 1,500 2,711 103,324 1.2m Moderate Mild 100,500 Prevalent population 1,356 Mild & moderate population,708,609 Dx'd population,292,537,330 Tx'd population Source: Plassman (2007), IMS Claims Data, Internal Roche/GNE Data 34

No. of Patients in 2012 (000s) Alzheimer s Disease 5EU target population The target population of diagnosed, treated Mild, Moderate and Severe Alzheimer s patients is ~1,20000 2012 potential EU5 target population 300 2,500,365 Alzheimer's Severe 200 138 Moderate 1,500 2,806,336 1.2m Mild 100,500 Prevalent population 1,403 Mild & moderate population,733,630 Dx'd population,302,555,341 Tx'd population Source: Plassman (2007), IMS Claims Data, Internal Roche/GNE Data 35

Global prevalence of chronic HBsAg infection HBsAg Prevalence 8% - High 2-7% - Intermediate <2% - Low WHO estimate ~350 million global chronic HBV infections Source: WHO Hepatitis B Department of Communicable Diseases Surveillance and Response Report, WHO/CDS/CSR/LYO/2002.2: Hepatitis B. 36

Chronic HBsAg patients (N) Chronic HBsAg prevalence in Developed Markets (France, Germany, Italy and A) 2012 potential target population,3.0,2.5,2.0 2.5m 2.0m,1.5,1.0.5.0 0.7m 0.8m 2010 2025 Chronic anti-hbsag Diagnosed chronic anti-hbsag 37

Chronic HBsAg patients (N) Chronic HBsAg prevalence in Emerging Markets (China [urban], Brazil, Turkey) 2012 potential target population,100.0,80.0 88m,60.0,40.0,20.0 41m 51m 24m.0 2010 2025 Chronic anti-hbsag Diagnosed chronic anti-hbsag

Number of patients with ACS & T2D (excluding CHF stage II-IV, 000 s) Aleglitazar Objective: Reduction of CV mortality, non-fatal MI, stroke, following a recent ACS in adults with concomitant T2D. 800 700 600 500 400 300 Top 5EU 200 100 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Source: Internal Roche and Genentech forecasts using National Center for Health Statistics NHANES () and country-specific data (ex-) 39